West-Ward brings generic Aloxi to market
West-Ward Pharmaceuticals, the U.S. subsidiary of Hikma Pharmaceuticals, has launched its generic Aloxi (palonosetron hydrochloriden injection). The drug is indicated to prevent acute nausea and vomiting associated with chemotherapy in adults. West-Ward’s generic Aloxi is the third generic of the product to launch in recent weeks.
“We are very pleased to add Palonosetron HCI Injection to our oncology portfolio,” West-Ward injectables division CEO Riad Mechlauoui said. “The launch of this product further expands our broad Injectables portfolio, bringing value to our customers and patients in the US hospital setting, as well as driving long-term, sustainable growth for our business.”
The drug, which the company is introducing in 0.25 mg/2 ml dosage strength, had a U.S. market size of $447 million for the 12 months ended January 2018.
FDA approves Amerigen’s generic cyclophosphamide
The Food and Drug Administration has approved Amerigen Pharmaceuticals’ abbreviated new drug application for two dosage strengths of its cyclophosphamide capsules. The drug, a generic of West-Ward’s product, is an anti-neoplastic agent indicated to treat various cancers.
Amerigen’s generic cyclophosphamide will be available in 25- and 50-mg capsules. The company said it plans to launch the drug soon, manufactured by Irvine Pharmaceuticals.
FDA approval spurs launch of Lupin’s generic Clobex Spray
The same week Lupin received approval from the Food and Drug Administration for its generic Clobex Spray (clobetasol propionate spray, 0.05%), the company launched the drug.
Baltimore-based Lupin’s generic Clobex Spray is a treatment for moderate-to-severe plaque psoriasis that affects up to 20% body surface area in patients ages 18 years old and older.
The product had a market size of roughly $30.5 million for the 12 months ended January 2018, according to IQVIA data.